A Zbtb7a proto-oncogene as a novel target for miR-125a

Nozomi Hojo1, Naoya Tatsumi1, Nahoko Moriguchi1

  • 1Department of Functional Diagnostic Science, Osaka University Graduate School of Medicine, Osaka, Japan.

Molecular Carcinogenesis
|December 30, 2015
PubMed

Insights

MicroRNA-125a (miR-125a) acts as a tumor suppressor by targeting the Zbtb7a oncogene. This interaction is crucial for regulating cell proliferation and apoptosis in lung cancer, highlighting a new therapeutic target.

Area of Science:

  • Molecular Biology
  • Oncology
  • Gene Regulation

Background:

  • Previous studies indicated miR-125a targets WT1 oncogene and acts as a tumor suppressor, downregulated in various cancers.
  • Understanding miR-125a targets is crucial for elucidating its tumor suppressor functions.

Purpose of the Study:

  • To identify novel targets of miR-125a.
  • To investigate the role of Zbtb7a as a direct miR-125a target in lung cancer.

Main Methods:

  • Gene expression profiling in miR-125a knockout mice.
  • Bioinformatics target prediction.
  • EGFP-3'UTR reporter assay to confirm direct binding.
  • siRNA knockdown of Zbtb7a.
  • Analysis of non-small cell lung cancer tissues.

Main Results:

  • Zbtb7a oncogene identified as a potential miR-125a target.
  • miR-125a directly suppresses Zbtb7a expression via binding to its 3'UTR.
  • Zbtb7a knockdown inhibits lung cancer cell proliferation and induces cell cycle arrest and apoptosis.
  • Negative correlation observed between miR-125a and Zbtb7a expression in lung cancer tissues.

Conclusions:

  • Zbtb7a is a direct target of miR-125a, involved in lung cancer cell cycle progression and apoptosis.
  • Deregulation of the miR-125a-Zbtb7a pathway is linked to lung cancer development and progression.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
4.3K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
24.6K
MicroRNAs01:22

MicroRNAs

12.0K
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
11.9K